Allogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I study - PubMed
3 hours ago
- #allogeneic
- #CAR-T cell therapy
- #solid tumors
- Study evaluates UTAA06, an allogeneic B7-H3-targeted CAR-Vδ1T cell therapy, in advanced solid tumors.
- Ten patients with various cancers received UTAA06 after lymphodepletion chemotherapy across three dose levels.
- Primary endpoint was safety; secondary endpoints included pharmacokinetics and anti-tumor efficacy.
- UTAA06 showed a manageable safety profile with no GvHD and limited Grade 1 CRS events.
- One dose-limiting toxicity (Grade 3 pneumonitis) occurred at the lowest dose level.
- Biological activity observed (transient tumor marker reductions in 50% of patients), but no objective RECIST responses.
- Limited CAR-T cell persistence attributed to subclinical host-versus-graft rejection (HvGR).
- Proof-of-concept established for safety and biological activity, but efficacy limited by immune rejection.
- Future strategies needed to improve durability and therapeutic potential of allogeneic CAR-Vδ1T cells.